Zkusit zdarma
Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.

GLUE
Cena:
$ 18.81
-0.07 (-0.37%)
Valuace
70
Růst
0
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

7:00 20-05-2026

BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-st...

Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates

12:16 07-05-2026

Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.45 per share versus the Zacks Co...

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise

13:33 21-04-2026

A GLUE executive disposed of 8,000 shares for a transaction value of approximately $141,000 at a wei...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.80 Average PT from Analysts

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.80 Average PT from Analysts

3:17 30-03-2026

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) has been given an average recommendat...

Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates

9:26 17-03-2026

Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.55 per share versus the Zacks Co...

Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

11:01 12-03-2026

Monte Rosa Therapeutics (GLUE) possesses the right combination of the two key ingredients for a like...

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

7:00 23-02-2026

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-s...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of “Moderate Buy” by Brokerages

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of “Moderate Buy” by Brokerages

5:24 11-01-2026

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) have earned a consensus rec...

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

22:49 08-01-2026

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc . (“Monte Rosa”) (Nasdaq:...

GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug

GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug

12:10 08-01-2026

Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradati...

Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable

Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable

9:55 08-01-2026

Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a gre...

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

16:01 07-01-2026

BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: ...

Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why

Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why

13:01 07-01-2026

Monte Rosa Therapeutics (GLUE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing...

Monte Rosa's Experimental Drug Slashes Inflammation Linked To Heart Disease

Monte Rosa's Experimental Drug Slashes Inflammation Linked To Heart Disease

10:09 07-01-2026

Monte Rosa revealed positive interim Phase 1 data of MRT-8102. Data showed safety, tolerability, and...

Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and NextCure (NASDAQ:NXTC)

Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and NextCure (NASDAQ:NXTC)

2:14 21-12-2025

Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and NextCure (NASDAQ: NXTC - Get Free Repor...

Monte Rosa Scores A Win In Prostate Cancer, And Rockets To A Four-Year High

Monte Rosa Scores A Win In Prostate Cancer, And Rockets To A Four-Year High

13:34 16-12-2025

Monte Rosa Therapeutics surged Tuesday after the biotech said every patients in a prostate cancer st...

BETTY NAMED CREATIVE AGENCY OF RECORD FOR GORILLA GLUE

BETTY NAMED CREATIVE AGENCY OF RECORD FOR GORILLA GLUE

9:00 19-11-2025

Agency will partner with Gorilla Glue on creative campaigns that build on the brand's toughness equi...

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

9:30 06-11-2025

Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.33 per share versus the Zacks Co...

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

7:00 06-11-2025

Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, provi...

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

7:00 03-11-2025

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-s...

close

MONTE ROSA THERAPEUTICS ANNOUNCES PRICING OF $300 MILLION UNDERWRITTEN PUBLIC OFFERING

08-01-2026
BOSTON, JAN. 08, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC . (“MONTE ROSA”) (NASDAQ:...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

07-01-2026
BOSTON, JAN. 07, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (“MONTE ROSA”) (NASDAQ: ...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 DATA OF MRT-8102 DEMONSTRATING PROFOUND CRP REDUCTIONS IN ELEVATED CVD-RISK SUBJECTS

07-01-2026
IN SUBJECTS WITH ELEVATED CARDIOVASCULAR DISEASE (CVD) RISK, MRT-8102, A NEK7-DIRECTED MOLECULAR GLU...
Více zde

MONTE ROSA THERAPEUTICS TO PRESENT INTERIM MRT-8102 PHASE 1 STUDY RESULTS

06-01-2026
BOSTON, JAN. 06, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-S...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES COMPELLING CLINICAL ACTIVITY OF MRT-2359 IN COMBINATION WITH ENZALUTAMIDE IN HEAVILY PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH ANDROGEN RECEPTOR MUTATIONS

16-12-2025
IN MCRPC PATIENTS WITH ANDROGEN RECEPTOR (AR) MUTATIONS, TREATMENT WITH MRT-2359 IN COMBINATION WITH...
Více zde

MONTE ROSA THERAPEUTICS TO PRESENT UPDATED MRT-2359 PHASE 1/2 STUDY RESULTS

15-12-2025
BOSTON, DEC. 15, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-S...
Více zde

BETTY NAMED CREATIVE AGENCY OF RECORD FOR GORILLA GLUE

19-11-2025
AGENCY WILL PARTNER WITH GORILLA GLUE ON CREATIVE CAMPAIGNS THAT BUILD ON THE BRAND'S TOUGHNESS EQUI...
Více zde

MONTE ROSA THERAPEUTICS PRESENTS PRECLINICAL DATA AT AHA SCIENTIFIC SESSIONS 2025 ON THE POTENTIAL OF MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER, TO TREAT CARDIOVASCULAR AND CARDIOMETABOLIC DISEASES

08-11-2025
DATA SUPPORT NEK7 AS A POTENTIAL NOVEL AND DIFFERENTIATED THERAPEUTIC APPROACH TO MODULATE THE NLRP3...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

06-11-2025
SECOND AGREEMENT SIGNED WITH NOVARTIS TO DEVELOP NOVEL DEGRADERS FOR IMMUNE-MEDIATED DISEASES, PROVI...
Více zde

MONTE ROSA THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

03-11-2025
BOSTON, NOV. 03, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-S...
Více zde

MONTE ROSA THERAPEUTICS PRESENTS PRECLINICAL DATA AT ACR CONVERGENCE 2025 ON THE POTENTIAL OF MRT-6160, A VAV1-DIRECTED MOLECULAR GLUE DEGRADER, TO TREAT IMMUNE-MEDIATED DISEASES

24-10-2025
MRT-6160 INHIBITED DISEASE PATHOLOGY, INCLUDING PROTEINURIA, LYMPHADENOPATHY, SKIN LESION FORMATION,...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES COLLABORATION WITH NOVARTIS FOR DEGRADERS TO TREAT IMMUNE-MEDIATED DISEASES

15-09-2025
NOVARTIS RECEIVES AN EXCLUSIVE LICENSE TO AN UNDISCLOSED DISCOVERY TARGET NOVARTIS ALSO RECEIVES OPT...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES COLLABORATION WITH NOVARTIS FOR DEGRADERS TO TREAT IMMUNE-MEDIATED DISEASES

15-09-2025
NOVARTIS RECEIVES AN EXCLUSIVE LICENSE TO AN UNDISCLOSED DISCOVERY TARGET NOVARTIS ALSO RECEIVES OPT...
Více zde

MONTE ROSA THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

02-09-2025
BOSTON, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

07-08-2025
PHASE 1 STUDY OF NEK7-DIRECTED MOLECULAR GLUE DEGRADER (MGD) MRT-8102 UNDERWAY, TO INVESTIGATE A POT...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 STUDY OF MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER FOR THE TREATMENT OF MULTIPLE INFLAMMATORY DISEASES

21-07-2025
MRT-8102 PHASE 1 STUDY INCLUDES SINGLE AND MULTIPLE ASCENDING DOSE COHORTS IN HEALTHY VOLUNTEERS AND...
Více zde

MONTE ROSA ANNOUNCES PUBLICATION IN SCIENCE OF KEY INSIGHTS THAT ENABLE NEXT GENERATION MOLECULAR GLUE DEGRADER MEDICINES

03-07-2025
BOSTON, JULY 03, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-S...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER FOR THE TREATMENT OF MULTIPLE INFLAMMATORY DISEASES

10-06-2025
MONTE ROSA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR MRT-8102, A NEK7-DIRECTED MOL...
Více zde

MONTE ROSA THERAPEUTICS TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

28-05-2025
BOSTON, MAY 28, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-ST...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

08-05-2025
VAV1-DIRECTED MRT-6160 PROGRAM ADVANCING TOWARD MULTIPLE PHASE 2 STUDIES, ENABLED BY PHASE 1 SAD/MAD...
Více zde

MONTE ROSA THERAPEUTICS PRESENTS PRECLINICAL DATA AT AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2025 ON THE POTENTIAL OF ITS CDK2-DIRECTED MOLECULAR GLUE DEGRADER TO TREAT HR-POSITIVE/HER2-NEGATIVE BREAST CANCER

28-04-2025
CDK2 MOLECULAR GLUE DEGRADER (MGD) IN COMBINATION WITH CDK4/6 INHIBITION AND ANTI-ESTROGEN THERAPY A...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES FOURTH QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE INCLUDING NEW CLINICAL RESULTS FROM MRT-6160 AND MRT-2359 PROGRAMS

20-03-2025
RESULTS OF THE MRT-6160 PHASE 1 SAD/MAD STUDY DEMONSTRATE DEEP VAV1 DEGRADATION OF GREATER THAN 90%,...
Více zde

MONTE ROSA THERAPEUTICS TO PRESENT PIPELINE UPDATE AND RELEASE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ON MARCH 20, 2025

11-03-2025
COMPANY TO PRESENT CLINICAL RESULTS FROM PHASE 1 SAD/MAD STUDY OF VAV1-DIRECTED MOLECULAR GLUE DEGRA...
Více zde

MONTE ROSA THERAPEUTICS TO PRESENT AT THE TD COWEN 45TH ANNUAL HEALTH CARE CONFERENCE

24-02-2025
BOSTON, FEB. 24, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-S...
Více zde

MONTE ROSA THERAPEUTICS TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

06-01-2025
BOSTON, JAN. 06, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-S...
Více zde

MONTE ROSA THERAPEUTICS APPOINTS DR. ERIC A. HUGHES TO BOARD OF DIRECTORS

13-12-2024
BOSTON, DEC. 13, 2024 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES CLOSING OF GLOBAL LICENSE AGREEMENT WITH NOVARTIS TO ADVANCE T AND B CELL-MODULATING VAV1-DIRECTED MOLECULAR GLUE DEGRADERS

11-12-2024
BOSTON, DEC. 11, 2024 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-S...
Více zde

MONTE ROSA THERAPEUTICS PROVIDES DEVELOPMENT PROGRESS UPDATE FOR ONGOING MRT-2359 PHASE 1/2 STUDY IN PATIENTS WITH MYC-DRIVEN SOLID TUMORS

05-12-2024
RESULTS FROM DOSE ESCALATION ARMS OF PHASE 1/2 STUDY OF MRT-2359 DEMONSTRATED A FAVORABLE SAFETY PRO...
Více zde

MONTE ROSA THERAPEUTICS TO PARTICIPATE IN THE PIPER SANDLER HEALTHCARE CONFERENCE

26-11-2024
BOSTON, NOV. 26, 2024 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-S...
Více zde

MONTE ROSA THERAPEUTICS ANNOUNCES GLOBAL LICENSE AGREEMENT WITH NOVARTIS TO ADVANCE T AND B CELL-MODULATING VAV1-DIRECTED MOLECULAR GLUE DEGRADERS

28-10-2024
AGREEMENT EXPECTED TO ACCELERATE MRT-6160 CLINICAL DEVELOPMENT AND BROADLY EXPLORE THERAPEUTIC OPPOR...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-02-10 00:00:008-KStáhnout
2026-01-09 00:00:008-KStáhnout
2026-01-07 00:00:008-KStáhnout
2025-12-16 00:00:008-KStáhnout
2025-11-06 00:00:008-KStáhnout
2025-11-06 00:00:0010-QStáhnout
2025-09-15 01:00:008-KStáhnout
2025-09-15 00:00:008-KStáhnout
2025-08-07 01:00:008-KStáhnout
2025-08-07 01:00:0010-QStáhnout
2025-08-07 00:00:008-KStáhnout
2025-08-07 00:00:0010-QStáhnout
2025-06-13 01:00:008-KStáhnout
2025-06-13 00:00:008-KStáhnout
2025-05-08 01:00:008-KStáhnout
2025-05-08 01:00:0010-QStáhnout
2025-05-08 00:00:008-KStáhnout
2025-05-08 00:00:0010-QStáhnout
2025-03-20 00:00:008-KStáhnout
2025-03-20 00:00:0010-KStáhnout
2025-03-19 23:00:008-KStáhnout
2025-03-19 23:00:0010-KStáhnout
2025-01-10 00:00:008-KStáhnout
2025-01-09 23:00:008-KStáhnout
2024-12-13 00:00:008-KStáhnout
2024-12-12 23:00:008-KStáhnout
2024-12-05 00:00:008-KStáhnout
2024-12-04 23:00:008-KStáhnout
2024-11-07 00:00:008-KStáhnout
2024-11-07 00:00:0010-QStáhnout
2024-11-06 23:00:008-KStáhnout
2024-11-06 23:00:0010-QStáhnout
2024-10-28 00:00:008-KStáhnout
2024-10-27 23:00:008-KStáhnout
2024-08-08 01:00:008-KStáhnout
2024-08-08 01:00:0010-QStáhnout
2024-08-08 00:00:008-KStáhnout
2024-08-08 00:00:0010-QStáhnout
2024-06-27 01:00:008-KStáhnout
2024-06-27 00:00:008-KStáhnout
2024-06-12 01:00:008-KStáhnout
2024-06-12 00:00:008-KStáhnout
2024-05-30 01:00:008-KStáhnout
2024-05-30 00:00:008-KStáhnout
2024-05-16 01:00:008-KStáhnout
2024-05-16 00:00:008-KStáhnout
2024-05-09 01:00:008-KStáhnout
2024-05-09 01:00:0010-QStáhnout
2024-05-09 00:00:008-KStáhnout
2024-05-09 00:00:0010-QStáhnout
2024-05-02 01:00:008-KStáhnout
2024-05-02 00:00:008-KStáhnout
2024-03-14 00:00:008-KStáhnout
2024-03-14 00:00:0010-KStáhnout
2024-03-13 23:00:008-KStáhnout
2024-03-13 23:00:0010-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2023-11-09 00:00:008-KStáhnout
2023-11-09 00:00:0010-QStáhnout
2023-11-08 23:00:008-KStáhnout
2023-11-08 23:00:0010-QStáhnout
2023-10-26 01:00:008-KStáhnout
2023-10-26 00:00:008-KStáhnout
2023-10-17 01:00:008-KStáhnout
2023-10-17 00:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 01:00:0010-QStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-10 00:00:0010-QStáhnout
2023-07-26 01:00:008-KStáhnout
2023-07-26 00:00:008-KStáhnout
2023-06-14 01:00:008-KStáhnout
2023-06-14 00:00:008-KStáhnout
2023-05-11 01:00:008-KStáhnout
2023-05-11 01:00:0010-QStáhnout
2023-05-11 00:00:008-KStáhnout
2023-05-11 00:00:0010-QStáhnout
2023-03-23 00:00:008-KStáhnout
2023-03-22 23:00:008-KStáhnout
2023-03-16 00:00:008-KStáhnout
2023-03-16 00:00:0010-KStáhnout
2023-03-15 23:00:008-KStáhnout
2023-03-15 23:00:0010-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-11-10 00:00:008-KStáhnout
2022-11-10 00:00:0010-QStáhnout
2022-11-09 23:00:008-KStáhnout
2022-11-09 23:00:0010-QStáhnout
2022-10-24 01:00:008-KStáhnout
2022-10-24 00:00:008-KStáhnout
2022-08-11 01:00:008-KStáhnout
2022-08-11 01:00:0010-QStáhnout
2022-08-11 00:00:008-KStáhnout
2022-08-11 00:00:0010-QStáhnout
2022-06-15 01:00:008-KStáhnout
2022-06-15 00:00:008-KStáhnout
2022-05-11 01:00:008-KStáhnout
2022-05-11 01:00:0010-QStáhnout
2022-05-11 00:00:008-KStáhnout
2022-05-11 00:00:0010-QStáhnout
2022-03-29 01:00:008-KStáhnout
2022-03-29 01:00:0010-KStáhnout
2022-03-29 00:00:008-KStáhnout
2022-03-29 00:00:0010-KStáhnout
2022-01-10 00:00:008-KStáhnout
2022-01-09 23:00:008-KStáhnout
2021-12-15 00:00:008-KStáhnout
2021-12-14 23:00:008-KStáhnout
2021-11-12 00:00:008-KStáhnout
2021-11-11 23:00:008-KStáhnout
2021-11-10 00:00:0010-QStáhnout
2021-11-09 23:00:0010-QStáhnout
2021-08-12 01:00:008-KStáhnout
2021-08-12 01:00:0010-QStáhnout
2021-08-12 00:00:008-KStáhnout
2021-08-12 00:00:0010-QStáhnout
2021-06-28 01:00:008-KStáhnout
2021-06-28 00:00:008-KStáhnout
preloader